#United States #New York #Class Action #Caribou Biosciences #CRBU

Class Action Lawsuit Filed Against Caribou Biosciences, Inc. (CRBU)

On January 21, 2025, a class action securities lawsuit was announced by Levi & Korsinsky, LLP regarding Caribou Biosciences, Inc. (NASDAQ: CRBU). This lawsuit aims to recover losses suffered by investors who were impacted by alleged securities fraud occurring between July 14, 2023, and July 16, 2024.

Overview of the Lawsuit

The legal complaint alleges that during the specified period, Caribou made misleading statements regarding its product, CB-010, which is a treatment for certain cancers. Specifically, the firm claims that the company overstated the safety, efficacy, and commercial viability of CB-010 compared to existing therapies, particularly autologous CAR-T cell treatments. Additionally, the lawsuit argues that Caribou faced significant financial risks that could jeopardize its operations and preclinical research initiatives.

Key Allegations

1. False Claims about CB-010: The lawsuit asserts that Caribou misrepresented the safety, efficacy, and clinical results of CB-010, thereby misleading investors about its market prospects.
2. Financial Instability: Allegations also point towards the company's potential lack of sufficient liquidity and capital to continue operations.
3. Misleading Statements: Overall, such misrepresentations could materially affect Caribou's business and operational capabilities, suggesting that the public information provided by the company was not only inaccurate but also deceptive.

What Investors Should Do

If you believe you suffered a loss while holding shares of Caribou Biosciences during the outlined period, it is essential to act quickly. The window to request the designation of lead plaintiff is open until February 24, 2025. However, participation in any recovery does not require you to serve in the role of lead plaintiff, providing an opportunity for broader involvement.

No Upfront Costs

Investors should note that joining this class action does not entail any financial obligation. Class members may receive compensation without incurring any out-of-pocket expenses, offering a no-risk opportunity to seek recovery for their losses.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securing damages for investors, Levi & Korsinsky is well established in the realm of securities litigation. The firm has been recognized for handling complex cases and has a team dedicated to supporting aggrieved shareholders. For seven consecutive years, they have been listed among the top firms in securities litigation, highlighting their capability and commitment to effective representation.

Contact Information

Investors affected by this situation can contact Levi & Korsinsky for more information. Inquiries can be directed to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at the following address:

Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: zlk.com

Stay informed and proactive during this crucial period. Your actions could significantly influence your financial recovery in this matter.

• ---